Fig. 2From: Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patientsState transition model of therapeutic options according to molecular test results. Notes: These transition models were linked to each decision tree branch. Each arrow indicates the possible transitions for each state. Legend: PD: progression disease; w: weekBack to article page